These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18455169)

  • 1. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence.
    van Westerloo DJ; Rauws EA; Hommes D; de Vos AF; van der Poll T; Powers BL; Fockens P; Dijkgraaf MG; Bruno MJ
    Gastrointest Endosc; 2008 Aug; 68(2):246-54. PubMed ID: 18455169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is prophylactic somatostatin effective to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis or hyperamylasemia? A randomized, placebo-controlled pilot trial.
    Wang ZK; Yang YS; Cai FC; Wang YH; Shi XL; Ding C; Li W
    Chin Med J (Engl); 2013 Jul; 126(13):2403-8. PubMed ID: 23823808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial.
    Li ZS; Pan X; Zhang WJ; Gong B; Zhi FC; Guo XG; Li PM; Fan ZN; Sun WS; Shen YZ; Ma SR; Xie WF; Chen MH; Li YQ
    Am J Gastroenterol; 2007 Jan; 102(1):46-51. PubMed ID: 17266687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
    Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
    Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
    Mansour-Ghanaei F; Joukar F; Taherzadeh Z; Sokhanvar H; Hasandokht T
    World J Gastroenterol; 2016 Jun; 22(21):5114-21. PubMed ID: 27275104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
    Lee KT; Lee DH; Yoo BM
    Pancreas; 2008 Nov; 37(4):445-8. PubMed ID: 18953260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic stents for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis should be inserted up to the pancreatic body or tail.
    Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Watanabe K; Nakamura J; Kikuchi H; Waragai Y; Takasumi M; Hikichi T; Ohira H
    World J Gastroenterol; 2018 Jun; 24(22):2392-2399. PubMed ID: 29904246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
    Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
    Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors.
    Christoforidis E; Goulimaris I; Kanellos I; Tsalis K; Demetriades C; Betsis D
    Endoscopy; 2002 Apr; 34(4):286-92. PubMed ID: 11932783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial.
    Yoo JW; Ryu JK; Lee SH; Woo SM; Park JK; Yoon WJ; Lee JK; Lee KH; Hwang JH; Kim YT; Yoon YB
    Pancreas; 2008 Nov; 37(4):366-70. PubMed ID: 18953247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial.
    Poon RT; Yeung C; Liu CL; Lam CM; Yuen WK; Lo CM; Tang A; Fan ST
    Gut; 2003 Dec; 52(12):1768-73. PubMed ID: 14633959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin for prevention of post-ERCP pancreatitis: a randomized, double-blind trial.
    Concepción-Martín M; Gómez-Oliva C; Juanes A; Díez X; Prieto-Alhambra D; Torras X; Sainz S; Villanueva C; Farre A; Guarner-Argente C; Guarner C
    Endoscopy; 2014 Oct; 46(10):851-6. PubMed ID: 24977398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis.
    Xiong GS; Wu SM; Zhang XW; Ge ZZ
    Braz J Med Biol Res; 2006 Jan; 39(1):85-90. PubMed ID: 16400468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of intraduodenal acetic acid infusion on pancreatic duct cannulation during endoscopic retrograde cholangiopancreatography: A double-blind, randomized controlled trial.
    Fang J; Wang SL; Zhao SB; Hu LH; Yao J; Shen Z; Gu L; Xia T; Cai Q; Li ZS; Bai Y
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1804-1810. PubMed ID: 29633339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic somatostatin can reduce incidence of post-ERCP pancreatitis: multicenter randomized controlled trial.
    Bai Y; Ren X; Zhang XF; Lv NH; Guo XG; Wan XJ; Nie ZG; Han ST; Bie P; Tian DA; Ji M; Li ZS
    Endoscopy; 2015 May; 47(5):415-20. PubMed ID: 25590178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
    Sherman S; Blaut U; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Earle D; Temkit M; Lehman GA
    Gastrointest Endosc; 2003 Jul; 58(1):23-9. PubMed ID: 12838216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
    Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
    Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of hyperamilasemia and pancreatitis after endoscopic retrograde cholangiopancreatography with rectal administration of indomethacin].
    Montaño Loza A; García Correa J; González Ojeda A; Fuentes Orozco C; Dávalos Cobián C; Rodríguez Lomelí X
    Rev Gastroenterol Mex; 2006; 71(3):262-8. PubMed ID: 17140047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
    Masci E; Cavallini G; Mariani A; Frulloni L; Testoni PA; Curioni S; Tittobello A; Uomo G; Costamagna G; Zambelli S; Macarri G; Innocenti P; Dragonetti C;
    Am J Gastroenterol; 2003 Oct; 98(10):2182-6. PubMed ID: 14572565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial.
    Tsujino T; Komatsu Y; Isayama H; Hirano K; Sasahira N; Yamamoto N; Toda N; Ito Y; Nakai Y; Tada M; Matsumura M; Yoshida H; Kawabe T; Shiratori Y; Omata M
    Clin Gastroenterol Hepatol; 2005 Apr; 3(4):376-83. PubMed ID: 15822043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.